11:40 AM EDT, 06/18/2024 (MT Newswires) -- Lexaria Bioscience ( LEXX ) said Tuesday that it hired a contract research organization to manage its 12-week chronic study, GLP-1-H24-4, to evaluate different DehydraTECH-GLP-1 formulations and other treatments, focusing on goals such as weight loss and reducing blood sugar levels.

Preparations for the study with the CRO have started under an initial start-up agreement. This includes activities like designing the full clinical protocol with medical experts, regulatory authority submissions, and planning data management, the company said.

Shares of the company rose nearly 3% in recent trading.

Price: 3.01, Change: +0.08, Percent Change: +2.73